Cargando…

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

INTRODUCTION: Type I interferons (IFNs) are implicated in the pathogenesis of systemic sclerosis (SSc). MEDI-546 is an investigational human monoclonal antibody directed against the type I IFN receptor. This Phase 1 study evaluated the safety/tolerability, pharmacokinetics (PK), immunogenicity, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldberg, Avram, Geppert, Thomas, Schiopu, Elena, Frech, Tracy, Hsu, Vivien, Simms, Robert W, Peng, Stanford L, Yao, Yihong, Elgeioushi, Nairouz, Chang, Linda, Wang, Bing, Yoo, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978926/ https://www.ncbi.nlm.nih.gov/pubmed/24559157 http://dx.doi.org/10.1186/ar4492

Ejemplares similares

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
por: Schiopu, Elena, et al.
Publicado: (2016)

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab
por: Forero, Andres, et al.
Publicado: (2013)

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
por: Becerra, Carlos R., et al.
Publicado: (2014)

546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
por: Stimes, Grant T, et al.
Publicado: (2023)

Medi-wiki worries?
por: Mason, Fred
Publicado: (2009)

MediNet: transfer learning approach with MediNet medical visual database
por: Reis, Hatice Catal, et al.
Publicado: (2023)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Inclusive jet production at $\sqrt{s} = 546 GeV$
por: Arnison, Geoffrey T J, et al.
Publicado: (1985)

Hepatic copper concentrations in 546 dogs (1982–2015)
por: Strickland, Jaimie M., et al.
Publicado: (2018)

546 Health Disparities Among Rural Burn Patients
por: Duggan, Robert P, et al.
Publicado: (2022)

Art, ciéncia i medi natural.
Publicado: (1994)

Medie and Info-pubmed: 2010 update
por: Ohta, Tomoko, et al.
Publicado: (2010)

Preludes and fugues BWV 544, 541, 546, 542 and 536
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
por: Agius, Mark A, et al.
Publicado: (2017)

MediVisión 3.2 para Windows.

Chocolate in History: Food, Medicine, Medi-Food
por: Lippi, Donatella
Publicado: (2013)

Dimuon production in proton-antiproton collisions at $\sqrt{s}$ = 546 GeV
por: Bauer, G
Publicado: (1986)

546 Malignancies Associated to Primary Immunodeficiencies. A 40 Year Review
por: España, Corin, et al.
Publicado: (2012)

546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018)

SUN-546 Coexistent Resistance to Thyroid Hormone Beta and Viral Thyroiditis
por: Golubic, Rajna, et al.
Publicado: (2019)

Challenging the Cost Effectiveness of Medi-Cal Managed Care
por: Riner, R. Myles
Publicado: (2009)

Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016)

Multiple diffraction theory of p$\overline{p}$ scattering at 546 GeV
por: Glauber, R J, et al.
Publicado: (1984)

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1(N546K) Mutation
por: Capone, Stephen, et al.
Publicado: (2022)

SAT546 Papillary Thyroid Cancer Surveillance: Thyroglobulin Levels Affected by HAMA
por: Perez, Julienne Sanchez, et al.
Publicado: (2023)

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
por: Annunziata, Christina M., et al.
Publicado: (2012)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease
por: Calverley, Peter M. A., et al.
Publicado: (2017)

Improving interMediAte Risk management. MARK study
por: Martí, Ruth, et al.
Publicado: (2011)

Financial Performance and Participation in Medicaid and Medi-Cal Managed Care
por: McCue, Michael J., et al.
Publicado: (2001)

MediDial cards: a quick win for service improvement
por: Davies, Mike, et al.
Publicado: (2014)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
por: Yang, Hui, et al.
Publicado: (2018)

Particle correlations in $\overline{p}$p collisions at 200, 546 and 900 GeV
por: Fuglesang, C
Publicado: (1988)

In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma
por: Zhou, Hui, et al.
Publicado: (2020)

P546: MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Elhaddad, Heba, et al.
Publicado: (2023)

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
por: Bauer, Todd M, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
por: Yu, Xiang-Qing, et al.
Publicado: (2016)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)

A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
por: Domachowske, Joseph B, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jmotloftr313qre83asn8jvg6d